Nasal Airflow Resistance

  • Nasal valve is the narrowest area of nasal airway1
  • Most common site of nasal airway obstruction1
  • Accounts for 2/3 of nasal resistance1

Small Changes Make Large Improvements to
Nasal Breathing

Bernoulli’s Principle: Increase in airflow velocity leads to a decrease in pressure

Poiseuille’s Law: Airflow is proportional to the 4th power of the change in radius

Non-Invasive Treatment with VivAer

  • Single solution to treat lateral wall, turbinate and septal swell body 
  • Durably remodels soft tissue, including cartilage, in the nasal valve 
    • Increases the radius of the nasal valve to improve airflow 
    • Shrinks submucosal tissue of the inferior turbinate 
    • Reduces soft tissue obstruction on the septum 
  • Treatment does not alter patient aesthetics 

Clinically Proven Durable Results
and High Patient Satisfaction

Significant NOSE Survey Results in Prospective, Multicenter Study 2

  • 89% of patients reported improved sleep quality
  • 94% of patients reported improved ability to breathe through their nose during exercise or exertion
  • Improvements shown in patients with static and dynamic valve collapse

*97% Responder rate for ≥15 point improvement in NOSE Scale score over baseline at 2 years.

Which Patients Can Benefit Most From VivAer?

  • Patients who have a NOSE score >60 and experience improvement with the modified Cottle’s maneuver
  • Postsurgical patients who have undergone nasal obstruction surgery and still have difficulty breathing
  • Patients seeking a low-risk, effective, non-surgical option for front-line treatment
  • Adjunct to surgery patients who are candidates for traditional surgery (e.g., septum, turbinates) and respond well to modified Cottle’s maneuver

Ready to Adopt VivAer Into Your Practice?

VivAer fits seamlessly into the office or OR environment. Many payers have coverage policies in place for the treatment of nasal airway obstruction. To learn more, contact Aerin Medical at (833)-484-8237

1 Clin. Otolaryngol. 1997, 22, 307-317; REVIEW Acoustic rhinometry; E.W.FISHER; ENT Department, Birmingham Heartlands Hospital, Birmingham, UK.
2 VivAer Stylus. Prospective, Non-randomized, Multi-Center Clinical Study. 39 Patients. Patient reported NOSE score and QOL survey. Endpoint from baseline to 24 months. Aerin Medical TR680-01.
3 VivAer Stylus. Prospective, Multi-Center, Non-Randomized Clinical Study. 50 patients. Endpoint from baseline to 12 weeks. Patient reported NOSE score. Aerin Medical TR470.